Zobrazeno 1 - 10
of 474
pro vyhledávání: '"Selpercatinib"'
Autor:
Hiroki Ohkoshi, Masafumi Saiki, Nozomu Takahashi, Kenta Homma, Satoshi Furuya, So Shimamura, Chisa Omori, Yuki Hoshino, Yoshinori Uchida, Shinnosuke Ikemura, Kenzo Soejima
Publikováno v:
Thoracic Cancer, Vol 15, Iss 25, Pp 1863-1866 (2024)
Abstract Selpercatinib is the first targeted therapy for rearranged during transfection (RET) fusion‐positive unresectable non‐small‐cell lung cancer (NSCLC). The main adverse effects of selpercatinib include hypertension, liver dysfunction, di
Externí odkaz:
https://doaj.org/article/716797d0b1244a2fadca993c1d2f1f18
Publikováno v:
JAAD Case Reports, Vol 50, Iss , Pp 138-140 (2024)
Externí odkaz:
https://doaj.org/article/00211d2071f04979bf191c1d3f93fd13
Publikováno v:
Lung Cancer: Targets and Therapy, Vol Volume 15, Pp 75-80 (2024)
Alexandria TM Lee,1 Sai-Hong Ignatius Ou2 1Department of Medicine, University of California Irvine School of Medicine, Orange, CA, 92868, USA; 2Chao Family Comprehensive Cancer Center, Orange, CA, 92868, USACorrespondence: Sai-Hong Ignatius Ou, Depar
Externí odkaz:
https://doaj.org/article/239290dacf054e06a8a3547851c8fc4e
Publikováno v:
Frontiers in Pharmacology, Vol 15 (2024)
AimsThe objective of this study is to compare the adverse events (AEs) associated with pralsetinib and selpercatinib.MethodsTo evaluate the imbalance of AEs linked to pralsetinib and selpercatinib in real-world data, the reporting odds ratio (ROR) wa
Externí odkaz:
https://doaj.org/article/115363d2b28a404aadedd91fecaebd8a
Publikováno v:
Endocrine Oncology, Vol 3, Iss 1, Pp 1-16 (2024)
Objective: The treatment landscape for thyroid cancers has changed rapidly with the availability of kinase inhibitors against VEGFR, BRAF, MEK, NTRK, and RET. We provide an up-to-date review of the role of kinase inhibitors in thyroid cancer and disc
Externí odkaz:
https://doaj.org/article/6f623931aafc4aefafe091a5859235b3
Publikováno v:
Heliyon, Vol 10, Iss 11, Pp e31681- (2024)
Background: Selpercatinib is effective in the treatment of RET-altered medullary thyroid carcinoma (MTC). This study aimed to evaluate the efficacy and safety of selpercatinib in the treatment of patients with RET-altered MTC. Methods: PubMed, Embase
Externí odkaz:
https://doaj.org/article/5011557c198b4314b13fbd01103d4ed7
Autor:
Carla Gambale, Alessandro Prete, Chiara Romei, Alessandro Celi, Rossella Elisei, Antonio Matrone
Publikováno v:
European Thyroid Journal, Vol 13, Iss 5, Pp 1-7 (2024)
Highly selective RET inhibitor selpercatinib has demonstrated notable efficacy in advanced/progressive RET-mutant medullary thyroid cancer (MTC) patients. However, despite a more tolerable toxicity profile than multikinase inhibitors, peculiar advers
Externí odkaz:
https://doaj.org/article/9480507b61a340388a13e61b404ed49b
Publikováno v:
Cancer Research, Statistics, and Treatment, Vol 7, Iss 1, Pp 82-90 (2024)
Rearranged during transfection (RET) alteration promotes oncogenesis in a few cancers. RET mutation positivity is seen in approximately 70% of medullary thyroid cancers, around 30% of differentiated papillary thyroid cancers, and 1-2% of non-small-ce
Externí odkaz:
https://doaj.org/article/fdaf1d450e3c400c8afe9c3af70b8c4f
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
Metastatic lung neuroendocrine carcinomas provide diagnostic challenges in identifying the cell of origin. High level calcitonin expression is not pathognomonic for medullary thyroid cancer. Tumor mutation analysis may provide essential clues regardi
Externí odkaz:
https://doaj.org/article/f812c41a3bf94716b2b4fb487bd51b37
Autor:
Elisa De Carlo, Elisa Bertoli, Monica Schiappacassi, Brigida Stanzione, Alessandro Del Conte, Roberto Doliana, Michele Spina, Alessandra Bearz
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
Over the past decade, molecular characterization has led to change the management of advanced non-small cell lung cancer (NSCLC) harboring driver mutations. Rearranged during transfection (RET) gene fusions, occurring in 1% to 2% of NSCLC, have emerg
Externí odkaz:
https://doaj.org/article/bba8322347704220a1e389f3fbdd3567